Neuronetics, Inc. (NASDAQ:STIM - Free Report) - Research analysts at William Blair lowered their Q2 2025 earnings per share estimates for Neuronetics in a note issued to investors on Tuesday, May 6th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.08). The consensus estimate for Neuronetics' current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics' Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.10) EPS.
Neuronetics (NASDAQ:STIM - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The business had revenue of $31.98 million during the quarter, compared to analyst estimates of $29.07 million. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%.
Separately, Canaccord Genuity Group boosted their price target on Neuronetics from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th.
Check Out Our Latest Research Report on Neuronetics
Neuronetics Stock Down 3.8%
Shares of NASDAQ:STIM traded down $0.17 during trading on Friday, hitting $4.28. 548,565 shares of the company were exchanged, compared to its average volume of 731,038. The stock has a market cap of $281.71 million, a price-to-earnings ratio of -3.48 and a beta of 1.92. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. The firm has a fifty day moving average price of $4.22 and a two-hundred day moving average price of $2.88. Neuronetics has a fifty-two week low of $0.52 and a fifty-two week high of $5.92.
Insider Buying and Selling at Neuronetics
In related news, CFO Stephen Furlong sold 17,307 shares of Neuronetics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total transaction of $71,131.77. Following the completion of the sale, the chief financial officer now owns 454,420 shares of the company's stock, valued at approximately $1,867,666.20. The trade was a 3.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 19,551 shares of company stock worth $81,185 over the last ninety days. Insiders own 8.70% of the company's stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of STIM. JPMorgan Chase & Co. grew its position in shares of Neuronetics by 10,954.1% in the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock valued at $88,000 after purchasing an additional 54,442 shares during the last quarter. Tradewinds LLC. bought a new stake in Neuronetics in the 4th quarter valued at $32,000. Geode Capital Management LLC boosted its stake in Neuronetics by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock valued at $506,000 after purchasing an additional 8,466 shares during the period. XTX Topco Ltd acquired a new position in Neuronetics in the 4th quarter valued at $49,000. Finally, Balyasny Asset Management L.P. increased its position in Neuronetics by 29.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after buying an additional 337,539 shares during the period. 53.59% of the stock is owned by institutional investors.
About Neuronetics
(
Get Free Report)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Articles
Before you consider Neuronetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.
While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
